Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform - Top-Institutions - MDSpire

Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform

  • By

  • Linkai Li

  • Zhongyu Chen

  • Yunrui Yan

  • Lening Zhang

  • May 7, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Rutgers Cancer Institute of New Jersey
    Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

    Key Differentiators

    • Oncology

  • #3

    Vanderbilt University
    Vanderbilt University

    Nashville, Tennessee

    Key Differentiators

    • Oncology

  • #4

    The Wistar Institute
    The Wistar Institute

    Philadelphia, Pennsylvania

    Key Differentiators

    • Oncology

  • #5

    Baylor College of Medicine
    Baylor College of Medicine

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform

  • by Linkai Li, Zhongyu Chen, Yunrui Yan, Lening Zhang

  • May 7, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer